SGP was hoping for its IDEAL study (data were reported in early 2008), to demonstrate Pegintron superiority over Pegasys but that didn't happen. Inasmuch as Pegasys' superiority was quite established by the time SCH 900518 clinical program has progressed, you have a point.
Market Data 
Markets 
AI
